secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclarion, Inc. (ACON)
CIK:        0001635077
Form:       8-K
Filed at:   2025-04-23T23:59:59+00:00
Accession:  0001683168-25-002738
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclarion updates investor deck: $14.6M cash, UK payer approvals, CLARITY trial on track for interim Q2 2026
--------------------------------------------------------------------------------

- Cash on hand ~$14.6M as of Apr 9 2025 10-K; runway into Q3 2026; zero debt, no preferred shares, no near-term warrant overhang.
- Secured UK payer approvals: three of top four private medical insurers now cover Nociscan, representing 5.2M people.
- Pivotal CLARITY trial fully funded ($4.6M total); first patient estimated Q2 2025; interim results expected Q2 2026.
- Expanded U.S. physician referral and commercial support; CPT Category III codes 0609T/0611T in place; Nociscan list price $1,450 vs discogram $2,000-$5,000.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635077/000168316825002738/0001683168-25-002738-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635077/000168316825002738/aclarion_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-002738

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer